- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Erica Mayer on Improving Patient Adherence to Hormonal Therapies
Listening to patient concerns and issues and communicating with them can really help providers keep patients with breast cancer adherent to their hormonal therapies, said Erica Mayer, MD, MPH, assistant professor, medicine, Harvard Medical School.
Listening to patient concerns and issues and communicating with them can really help providers keep patients with breast cancer adherent to their hormonal therapies, said Erica Mayer, MD, MPH, assistant professor, medicine, Harvard Medical School.
Transcript
What tools can physicians employ to improve adherence of hormonal therapies among patients with breast cancer?
I think, you know, a major tool that providers can do to help maintain patients on therapy is communication and listening to how patients are doing assessing their symptoms and acting, and if a patient needs to take a short break, if we need to rotate from one aromatase inhibitor to another, if we need to explore a supportive care medicine, or having a patient try acupuncture exercise—there's a lot of strategies to use.
But I think the most important thing is if a patient is unhappy or uncomfortable or feels like they, they just can't do it, we need to know, and we need to work on that together, rather than not hearing each other and then having somebody stop therapy early.
Sociodemographic Factors Impact Cytoreductive Surgery Decisions in Advanced Ovarian Cancer
April 9th 2025Patients with advanced epithelial ovarian cancer who were non-Hispanic Black, older, had lower household income, resided in nonmetropolitan areas, and were unmarried had higher odds of refusing cytoreductive surgery.
Read More
Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD
April 8th 2025Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.
Read More
Meta-Analysis Finds SGLT2 Inhibitors Boost Hemoglobin, Hematocrit in CKD
April 8th 2025The analysis supports the integration of sodium-glucose cotransporter 2 (SGLT2) inhibitors into treatment paradigms for patients with chronic kidney disease (CKD) not only for their established benefits but also for addressing anemia.
Read More
